HOW IS THE OVERALL SAFETY FOR ETVEZA?
Overall tolerance and safety are good. The common adverse reactions are local reaction at injection site; others include headache, dizziness, rashes, insomnia and so on. According to literature, bacterial infection, tuberculosis, malignant tumor and so on might happen, however, the incidence proportion is low.
HIGH QUALITY WITH SAFETY AND EFFICACY
- The manufacturing process and specification of Etveza is highly similar to Innovator. The Amino Acid Sequence and Composition is exactly the same between Enbrel and Etveza.
- Etveza has launched in China since 2005, as the first biosimilar version of Etanercept globally.
- Etveza has benefited more than 500,000 patients in the past 14 years, with very good market response and reliable PSUR system. Outside of China, Etveza has been marketed successfully and approved in more than 14 countries globally.
